Lyra Therapeutics (LYRA) Assets Average (2020 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Assets Average of $39.9 million in Q4 2025, down 17.1% on a QoQ basis from $48.1 million in Q3 2025, and down 44.99% YoY from $72.6 million in Q4 2024.
Lyra Therapeutics (LYRA) Assets Average (2020 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Assets Average for 6 consecutive years, with $39.9 million the latest figure, recorded in Q4 2025.
- Assets Average for Q4 2025 came in at $39.9 million, down 44.99% year-over-year; the trailing twelve-month figure through Dec 2025 was $39.9 million (down 44.99% YoY), and the FY2025 annual result was $51.2 million, down 50.97% from the prior year.
- Assets Average for Q4 2025 stood at $39.9 million, down from $48.1 million in the prior quarter.
- The five-year high for Assets Average was $142.1 million in Q1 2024, with the low at $39.9 million in Q4 2025.
- A 5-year average of $87.7 million and a median of $81.8 million in 2021 frame the typical range for Assets Average.
- Across the five-year window, Assets Average surged 175.88% in 2021 and tumbled 56.83% in 2025, its largest moves.
- Lyra Therapeutics' Assets Average stood at $61.3 million in 2021, then surged by 87.09% to $114.7 million in 2022, then advanced by 14.71% to $131.6 million in 2023, then sank by 44.86% to $72.6 million in 2024, then slumped by 44.99% to $39.9 million in 2025.
- The last three Assets Average figures came in at $39.9 million (Q4 2025), $48.1 million (Q3 2025), and $54.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 39.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 39.91 Mn |
| Sep 30, 2025 | 48.14 Mn |
| Jun 30, 2025 | 54.44 Mn |
| Mar 31, 2025 | 61.33 Mn |
| Dec 31, 2024 | 72.55 Mn |
| Sep 30, 2024 | 86.67 Mn |
| Jun 30, 2024 | 118.05 Mn |
| Mar 31, 2024 | 142.06 Mn |
| Dec 31, 2023 | 131.59 Mn |
| Sep 30, 2023 | 123.13 Mn |
| Jun 30, 2023 | 109.77 Mn |
| Mar 31, 2023 | 101.92 Mn |
| Dec 31, 2022 | 114.72 Mn |
| Sep 30, 2022 | 124.75 Mn |
| Jun 30, 2022 | 88.69 Mn |
| Mar 31, 2022 | 51.11 Mn |
| Dec 31, 2021 | 61.31 Mn |
| Sep 30, 2021 | 72.05 Mn |
| Jun 30, 2021 | 74.62 Mn |
| Mar 31, 2021 | 76.87 Mn |